Power to the Patients
Michael Gold, Chief R&D Officer at Compass Pathways
August 26, 2025
In this episode, Brandon sits down with Dr. Michael Gold, Chief R&D Officer at Compass Pathways, to explore the art and science of running high-quality clinical trials. With nearly 30 years of experience across pharma giants like J&J and GSK, as well as small biotechs, Mike shares a masterclass on clinical operations—why the best study design means nothing without flawless execution, and how quality must always come before speed or cost. 

In this episode, Brandon sits down with Dr. Michael Gold, Chief R&D Officer at Compass Pathways, to explore the art and science of running high-quality clinical trials. With nearly 30 years of experience across pharma giants like J&J and GSK, as well as small biotechs, Mike shares a masterclass on clinical operations—why the best study design means nothing without flawless execution, and how quality must always come before speed or cost. 


Transcript

Michael Gold 0:00 The best clinically the best designed clinical trial, the best study, if it's not executed correctly, is useless.

Brandon Li 0:23 Mike, thanks so much for joining me on the show.

Michael Gold 0:26 Pleasure, Brian. Thank you for reminding me to be here.

Brandon Li 0:29 Yeah. Of course. Uh, I've been so looking forward to this, uh, for the audience. Uh, Mike is currently the chief r and d officer over at Compass Pathways, uh, the furthest, um, and largest, uh, player first, the long and largest player in, uh, uh, the really exciting psychedelic space. Um, but before that, he's had a storied career in, um, in research and, uh, and r and d. So, uh, Mike, may maybe just give us a quick background as to your career and how you got here.

Michael Gold 0:53 Sure. I'm I'm I'm tempted to start once upon a time there was, but you know, so, um, so I have I I, you know, um, I've been in industry now almost thirty years, which is hard to believe. Um, have been in both large and small companies, uh, behemoths like J and J and GSK. And I've also been in, you know, tiny biotech companies with less than 20 people. So, um, pretty much any neuroscience indication that you can think of, I've been involved in in in one way or another. Um, the drugs, drug device combinations, biologicals, diagnostics, so in that space as well. And from an industry perspective, you know, almost any stage you development from first in May and through multiple international studies, registration approvals, etcetera. So pretty much any aspect of the business that you can think of in a clinical development, uh, universe, I've actually worked in.

Brandon Li 1:46 Yeah. Now, uh, the the kinda theme of today is, uh, a bit of a clin ops masterclass. I'd I'd love to maybe just, um, have you tee up for me. Um, how do you think about the the kind of core responsibilities for, um, doing a great job at at Clinical Operations? , universe, I've actually worked in. Yeah. Now, uh, the the kinda theme of today is, uh, a bit of a clin ops masterclass. I'd I'd love to maybe just, um, have you tee up for me. Um, how do you think about the the kind of core responsibilities for, um, doing a great job at at Clinical Operations?

Michael Gold 2:01 Yeah. No. It's I love love the question, but let me let me then preface it by saying that I am not naturally a clin ops guy. Okay? I am a physician first and last. I'm a clinical development guy. I've had to back into operations because it's a necessary part of any good clinical development organization. And so I think the the the question being, you know, what is what is, you know, the the excellence part of it. Right? The best clinically, the best designed clinical trial, the best study, if it's not executed correctly is useless. Right? So it doesn't matter if you are a genius, you design the best study possible, and it's the killer experiment. If it's not run correctly, if the data are not of the appropriate quality, if you're not watching what's going on while you're making the soup, then what you end up with more often than not is not high quality data. It leads uninterpretable or difficult to interpret results. And at the end of the day, to me, it's fundamentally dis disrespectful of the patients and the participants that come into our clinical trials. Sure. So the operational aspect to to me is part of that contract with patients, with participants, because in some cases, the participants are healthy volunteers, not patients, but let's just say any any participant in the clinical trial. For me, it's part of that social contract that says, you know, you're putting your life in our hands. We're gonna stick needles in you. We're gonna confine you. We're gonna ask you all sorts of invasive questions. We're gonna take time out of your life. And the operational aspect to it is, please let's make sure that whatever data we're collecting, we're doing it right, and we're watching over the safety of participants in a clinical trial. So that's the lens to which I see clinical operations. It's not I'm not so much kind of a in the details about the particular CRF, etcetera, etcetera. We can get there, but I you know, as you ask me the question, what what comes back in the head in the back of my head is always integrity, the integrity of the clinical trial. Is it delivering data that allows us to answer a question in an unimpeachable manner?

Brandon Li 4:12 Yeah. You know, canonically, people will say that, uh, there's a trade off between, uh, speed, cost, and, um, and quality. Uh, you get to pick two of three. Um, how how do you think about that trade off? trial. Is it delivering data that allows us to answer a question in an unimpeachable manner? Yeah. You know, canonically, people will say that, uh, there's a trade off between, uh, speed, cost, and, um, and quality. Uh, you get to pick two of three. Um, how how do you think about that trade off?

Michael Gold 4:23 Yeah. So, I mean, look, I I was very fortunate to have a very, very good, uh, mentor early on in my career, and he made it very clear. Quality, time, cost in that rank order. You have mistakes with quality. You can't really undo the time or money. You know, other things you can play with, but that's the rank order. So I I'm kind of a stickler. I don't like or don't endorse any real compromises on quality. Because sometimes, in fact, you know, you really you don't catch the mistake until very late, And so there's no amount of time or money to make up for that. And then there's, I think sometimes a misconception that if you throw enough resources in terms of people or money, you can make up for shortcomings in quality and time, and that's not my experience. So I'm gonna repeat it in rank order, quality, time, money.

Brandon Li 5:18 Now, uh, I feel like, uh, to be a little challenging here, that's easy to say when you're running a program at Advi, um, but a little bit, uh, a little harder to say when you're, uh, at a at a smaller biotech.

Michael Gold 5:29 Yeah. You know, um, I'll take the challenge and I'll push back. It's even more critical in a small biotech because you don't have the resources to make up for mistakes to do it again, to do it again. Right? So there are companies out there and we know some of them and, you know, uh, there some of them are beloved in the neuroscience field where they ran a study, it didn't work out, they tweak it, fix it, go back at it again. Um, biotech doesn't have that luxury. So I actually take the position that and if it's just on quality, it's probably even more critical for biotech so we get it right the first

Brandon Li 6:04 time. So it it sounds to me like the maybe a an overarching principle is measured twice, cut once. o back at it again. Um, biotech doesn't have that luxury. So I actually take the position that and if it's just on quality, it's probably even more critical for biotech so we get it right the first time. So it it sounds to me like the maybe a an overarching principle is measured twice, cut once.

Michael Gold 6:14 Yeah. It's it's one way to put it. I mean, look, uh, you know, you can you can do the kind of, you know, um, carpenter surgeon thing, which is measure twice, cut once. Uh, there are other, you know, it's a it's about pressure testing your ideas. And again, you know, all of us who've been working in clinical development, I think the one thing we can agree on is we've never seen a perfect study. Every study, every study is a compromise between what you would like to do, what you can do, what you can afford to do, what you have the time to do, so there are always compromises. And so, you know, you safeguard as much as you can in terms of the quality, but the things that we can do across the board is to actually pressure test our ideas either with colleagues, friends, you know, ex external experts, um, consultants, etcetera, etcetera. You know, it it it it's it's not skin off anybody's back or challenge anybody's ego to put your ideas to the test and make sure that what you're thinking about is really, you know, stands stands up the pressure and and being pushed and prodded and examined.

Brandon Li 7:19 Is is the and is the is the ultimate, uh, I guess, safeguard to quality here really pressure testing ideas? Is that is that how how it comes through for you?

Michael Gold 7:28 It it's it's two things. One one is pressure testing ideas and making sure that you understand what you're getting into and where you are making trade offs. Right? And the other part about it is, you know, vigilance over the data as you're actually running the study. Are your data and these are both kind of, you know, clinical, but also operational data. Are you in your operational envelope? Right? Um, you had a model for recruitment and you're deviating. How early in that course are you actually willing to start taking action? Because one of the things that I see a lot is let's just wait a little bit longer. Let's just wait a little bit longer. Right? In some cases, the answer is we are not using data. We are not using analytics. We're not using other experience to sit there and say, I don't have to wait to see the full disaster. I can start to pick up signals much earlier. Right? Um, so so I would say, you know, almost obsessive vigilance over your data to make sure that you're picking up, you know, signals very early on. Um, and that's in in parallel with making sure that you are pressure testing before you put things into play.

Brandon Li 8:36 Yeah. I I'd love to maybe, like, go down both of those, um, angles. So there's a, uh, a design question. Are you making the right design decisions? And then it sounds like there's an operational, um, question around, uh, using data to properly make sure you're you're steering the ship.

Michael Gold 8:51 Um, uh, Yeah. I I'd love to maybe, like, go down both of those, um, angles. So there's a, uh, a design question. Are you making the right design decisions? And then it sounds like there's an operational, um, question around, uh, using data to properly make sure you're you're steering the ship. Um, uh,

Brandon Li 8:51 maybe let's start with with design first, uh, but I am a data guy, so I wanna get there. Um, from the design, like, standpoint, what what are the most important design decisions, um, that that you have to make?

Michael Gold 9:04 Well, my dear Padawan learner, there are so many I mean, I'm teasing. Right? I'm just teasing.

Brandon Li 9:09 No. No. No. I mean, uh, know how this is. get there. Um, from the design, like, standpoint, what what are the most important design decisions, um, that that you have to make?

Michael Gold 9:04 Well, my dear Padawan learner, there are so many I mean, I'm teasing. Right? I'm just teasing.

Brandon Li 9:09 No. No. No. I mean, uh, know how this is.

Michael Gold 9:11 Well, I mean, look. So so you sit there and you ask what what is the question that I'm most interested in answering. Right? And so then you think about which one of a thousand different designs allow you to get to your question most cleanly and most efficiently. Right? Mhmm. It comes down to, okay, so what's the patient population? What are you measuring? How are you gonna measure it? When are you gonna measure it? How often do you wanna measure it? Right? What is the control? Um, how do you actually manage heterogeneity in a population? What, you know, do you really need to stratify by 15 different things and, you know, how how strict are your inclusion exclusion criteria? So, you know, there are a dozen different axes that you are taking into consideration almost simultaneously to figure out, you know, what, what design, you know, what's the envelope with that design look like, right? So you start to think like an engineer, right? If you're designing a rocket or you're designing some, some, some, you know, there's an operational, there is a design envelope that you're thinking about, and and I'm using my hands to illustrate it. Right? Yeah. X, y, z time, etcetera, etcetera. But then the nice thing is that within within the clinical method clinical trial universe, there are different ways of approaching it. And so you start to think about what is what is a, you know, a family of designs. Do you really need an active control? Do you need placebo? Uh, can you do an adaptive design? Can you do, you know, single blind, double blind? So this is where, you know, being able to really put people together and ex with experience and knowledge, bring a whole bunch of options to the table, and then you can fairly quickly start to winnow them down and say, Okay, this is really interesting, but this family of study designs don't work. That family of study designs don't work. This is starting to zero in. And so this is part of the both creative but iterative process where you start to zero in or narrow down your options to to where where you think you have somebody that allows you to go after that question. And I'm I'm deliberately avoiding these excuse me, the issue of hypothesis testing versus hypothesis confirming. I I I, you know, I wanna avoid that, you know, it's a discussion for for for maybe later in the conversation. But you're asking the the the what is the research question? Right? Is there a signal for efficacy? How robust is that signal? How early can I pick it up? In what domains does that signal exist? Um, how important is it for me to show an exposure response relationship? And then I'll get into what is the mechanism, what is the target, you know, so it's you you ask a great question, but there this is this is, like, um, truly something where you're operating in parallel across many dimensions at the same time. Right? Yeah. And then you ask about the operational part of it, then I start to sit there. Okay. If I have an idea of what that study looks like, then I have to think about, is it feasible? Can I find these people? How fast can I find them? Where do I find them? Right? Are there are there is there a universe of reasonable clinical research sites or investigators that understand what we're trying to do, right, or have experience of what we're trying to do. Do the do the right instruments exist? Can I access them? You know? Are there so that starts to kind of peel other layers about kind of tactical implementation of the study as opposed to, you know, here here sort of the design parameters. Does that does that kinda help, Brandon? e experience of what we're trying to do. Do the do the right instruments exist? Can I access them? You know? Are there so that starts to kind of peel other layers about kind of tactical implementation of the study as opposed to, you know, here here sort of the design parameters. Does that does that kinda help, Brandon?

Brandon Li 12:57 Yeah. Yeah. Um, I feel like as you as you outline this, it feels like a dozen plus different design decisions that are all confounded. Um, they all influence one another. It's temp it's tempted to say, oh, let's run an objective function, an optimization function on here, and just spit out an ideal design, but I suspect that it's not that easy.

Michael Gold 13:20 Um, well, I I have to say if if you were doing a me too drug for something where there were, you know, 50 prior clinical trials, yeah, maybe. Right? Yeah. When you're doing a first in class like we are, there's no precedent for what we're doing. And so so the value of that kind of optimization is limited. That said, you know, we are we have to be students of history and look at prior studies in related fields to figure out where some of these things worked or did not work. Now this is one of the places where I think industry has done itself a disservice. We don't publish a lot of operational data. Well, the the the organizations that have a lot of this is actually CROs, but this is how they make their money. Right? If you wanted to understand what were the recruitment challenges or the retention challenges or quality challenges in a study, you're not gonna find that in publications. And so so that actually creates a a a problem for us in terms of figuring out the balance between a design and its and its implementability or it's it's yeah. It's an implementation.

Brandon Li 14:22 Yeah. And so so then, naturally, this is where, uh, the pressure testing comes into play. Um, how how does one pressure test once they've have maybe two or three candidate designs that, uh, you're excited about?

Michael Gold 14:32 Sure. Uh, so, I mean, what do you do when you wanna pressure test something? You go and you you you you share it with with colleagues in in the universe, so you share it with, you know, consultants out there or friends of friends, or sometimes even not friends, you know, people, people who are gonna challenge you, then you put it out there and say, poke holes in it, tell me what's wrong with it. Right? Mhmm. Why is this, I mean, there are some people out there that I know I I I can ask them, tell me how this is gonna fail. Yeah. And they will they'll without any shame or hesitation, tell me just how bad my design is and how many different ways it's going to fail, which is fine. It's what I'm what I get to know.

Brandon Li 15:08 Yeah. Bet better to better to know what the blind spots are, um, while you're, uh, while you're heading down the path. Right?

Michael Gold 15:15 Yeah. I mean, look, it's it's it's a lot easier to fix it upfront and kind of, you know, be prepared. E even if you agree that you're gonna take on a design that has risks, you at least know. Yeah. Now you're you're not walking it to while you're, uh, while you're heading down the path. Right? Yeah. I mean, look, it's it's it's a lot easier to fix it upfront and kind of, you know, be prepared. E even if you agree that you're gonna take on a design that has risks, you at least know. Yeah. Now you're you're not walking it to

Brandon Li 15:29 the blind. You you can

Michael Gold 15:30 you can now be for one and say, here are the watch outs. Right? Here we go.

Brandon Li 15:34 Right. Yeah. Um, and then I, I suppose this dovetails nicely into part two, which is, um, I like, I like the term you use, like your on your operational envelope, um, and being vigilant about the data. Um, how do you think about that? for one and say, here are the watch outs. Right? Here we go. Right. Yeah. Um, and then I, I suppose this dovetails nicely into part two, which is, um, I like, I like the term you use, like your on your operational envelope, um, and being vigilant about the data. Um, how do you think about that?

Michael Gold 15:49 Well, I mean, I think I think that that's, you know, look, this is this is where a really, really good collaboration between clinical scientists and study physicians and and clinical operations groups is critical. Right? The flow of data between those groups has to be, you know, absolutely seamless. Right? Um, and I'll give you I'll give you I'll give you, uh, an example from from a study that and I ran many years ago in a in a different company, and we were running a study that had a time to event endpoint. And, you know, we were not seeing enough events. It just it was just we're not seeing events. And after that study had been running for well over three years, we finally said, well, damn, it's futile. Let's just stop. Right? We're we obviously we obviously are missing something here. So it turned out to be as soon as as soon as we stopped the study, um, there were a whole bunch of events that were sitting in investigators' documents that were not put into the system. Oh, Lord. Well, in fact, there were plenty of events and it ended up favoring the intervention, so we got very lucky, but it drove home a message that, you know, um, if you're blind to the data or the data are not in your system and nobody's looking at it, I'm operating, you know, completely blindfolded. And so for me, this was one of, you know, if you are, you know, you're tracking or you're collecting particular data, you know, the, the, the rate at which it's coming in or the metadata around it, the quality of the data, the variability around it, how long does it take for some piece of information or a clinical trial to make it into your EDC? Those are kind of indicators of quality. You know, if it's taking sites forever to screen and enroll the first participant, you should be asking questions. What's going on here? Why is it so difficult for you? Right? Um, there are other things that you can look at at a at a site level that that can give you cause. Right? I mean, if there's a lot of turnover on a site, you have to ask why. What's what's going on. Right? So those are the kind of things that any operational team should be paying attention to and and can flag or raise a flag up and say, hey. There are issues with the study. Um, you know, studies, sometimes they are designed with a sort of canonical patient population in mind by people who are very smart and well intentioned. When you get out there, you can't find a participant. Right? Frank? Well,

Brandon Li 18:26 you know? Like, um, it strikes me as you describe this that there's, like, a a stream of data that's coming in that maybe you're you're checking weekly, um, so kinda sanity check, uh, in a in a DAC or or or of some sort. . When you get out there, you can't find a participant. Right? Frank? Well, you know? Like, um, it strikes me as you describe this that there's, like, a a stream of data that's coming in that maybe you're you're checking weekly, um, so kinda sanity check, uh, in a in a DAC or or or of some sort.

Michael Gold 18:38 I mean, ideally, it's real time. It's not even weekly. It's real time. And I get in organizations where heads of r and d or whatever, we had dashboards up. I could see exactly who was in the screening queue, who was in the, you know, the random I mean, I knew exactly at or in real time. I had a pulse on on on on the flow of participants in and out of our studies. Right?

Brandon Li 19:00 If you could design with me for a second your dream dashboard, like, what are what are all the indicators in real time that you would wanna be able to see? , the random I mean, I knew exactly at or in real time. I had a pulse on on on on the flow of participants in and out of our studies. Right? If you could design with me for a second your dream dashboard, like, what are what are all the indicators in real time that you would wanna be able to see?

Michael Gold 19:07 Uh, Yeah. Yeah. I know. That's I love that. Okay. So you so we're gonna design this one and you're gonna then you're gonna you're gonna Put it in a minute. Do it for you. You're gonna you. Right? Thank you. So one aspect of that is the pipeline, the inflow into the study, you know, prescreening, screening, randomization. What's the flow in? Right? What does it look like? What does it look like against some particular model where you work with whatever you're doing some, you know, some sort of ARIMA or you've got some sort of model in the back of your head about what your equipment should look like. Right? How's that fitting with the model? I'm also interested in the back end of it, which is how are we, how are we doing on retention of subjects? Right? Now I have to say some organizations are myopic. They will focus on recruitment, but not pay attention to retention. And at the end of the day, first patient is as important. The really important thing is last patient out. Right. Right. And if you can keep people in your study and reduce attrition and you can reduce missing data, well, the the the data geek in me feels much better because I have less of a missing data problem. So patient inflow, patient outflow. Right? And then there's a question about the data that we're collecting. A dashboard for me would tell me where are we in terms of missing data. You know, how many primary outcome measures are we missing? How's that looking over time? What is the pattern of missingness to the extent you can infer that, right? Complete assuming that we're in a blinded environment. And then what I would be looking for are diagnostics. Am I seeing excess variance? Am I seeing too many outliers? Is there a pattern, you know, in the data related to either geography or site or some other variable? Right? So I'm looking for some pattern recognition or indicator that there's something more systemic going on. And then you think lastly in sort of quality of the data. Right? Queries, deviations, protocol deviations, you know, safety issues. So, you know, I'd be tracking AEs, TAEs, SAEs over time to get a sense of, you know, where where where my data going. Right? So that that to me is sort of a a nice dashboard that kinda mixes clinical level insight with data quality level insight. It gives me a sense of where what is my operational envelope looking for. Right? You know, how are my sites activating in time? You know, time form site activation to first patient in and after that. Right. I want to know, are they actually on on are they on track? Right. Things like that.

Brandon Li 21:49 Yeah. And as you described this kinda dream world, like, how much of it do you have today versus, um, it doesn't feel like it's, like, it's kinda hard to get? activation to first patient in and after that. Right. I want to know, are they actually on on are they on track? Right. Things like that. Yeah. And as you described this kinda dream world, like, how much of it do you have today versus, um, it doesn't feel like it's, like, it's kinda hard to get?

Michael Gold 21:56 Um, I think we have we have a lot of it, but I but I would say it's not it's not frictionless to actually access it. It. Right? Sure. Right. And I and I think it's part of the part of the issue is that, you know, we we work with a CRO that works with multiple vendors, you know, their their, you know, sites have their own particular platforms, their academic institutions. So interoperability is a real problem in terms of getting the data to flow easily. Now layer that on top with, you know, data privacy issues, And, of course, you know, as the sponsor, I need to be arm's length from any individual patient data, so we need to make sure that the right data protection mechanisms are in place. Um, you know, ideally in that dashboard, I should be able to drill down or click down on some anomalous data and get to, you know, where is that really coming from. Right? I've seen that. That's doable. Absolutely doable. I've seen it done. It's it's just to me the the the the friction to actually make that sort of best practice. It's it's taken longer than I had hoped. Yeah.

Brandon Li 23:08 I've heard you describe running a clinical trial as part art and part science. Oh, yeah. What what do you mean by that? Absolutely doable. I've seen it done. It's it's just to me the the the the friction to actually make that sort of best practice. It's it's taken longer than I had hoped. Yeah. I've heard you describe running a clinical trial as part art and part science. Oh, yeah. What what do you mean by that?

Michael Gold 23:17 Well, I mean, the the science part of it is I think pretty clear. You know, there's a hypothesis, you have a kind of an experiment you're gonna conduct, you have an idea of how you're gonna measure the outcome, you know, you've got, you know, some quantitative, uh, parameters, so you have an effect size and variance and sample size and hour and alpha. So there's a kind of science in terms of how you end up in experiment. Right? And and a clinical trial is an experiment. No if, ands, or buts about it. The art part of it is that these are not lab animals. This is not a widget. These are human beings, and stuff happens. People get into car accidents. There are family issues. You know, people can't make it to a, to a, to a, to a session. Um, people take stuff they're not supposed to, somebody's husband or wife yells at them, you know? So there are all sorts of kind of things that interfere with the quote unquote clean conduct of, of, of a trial. I mean, look, let's say you're running a preclinical trial, right? Things happen fairly easily in terms of schedule, right? Missing data for a preclinical experience shouldn't really happen. Sorry, I'm getting over cold. Missing data in clinical trials is post and parcel with it. So the art of it is how do you how do you make a trial the least burdensome on participants without compromising the quality of the data that you want to collect, right? How far can you flex? So we have, for example, some treatment windows. We say you need to come in on day fourteen, plus or minus something. The something, the plus or minus, that's art. Is plus or minus two good enough? Can I make it plus or minus three? When does play, you know, so that that's where I can't tell you there's hard science around some of the things that we do to make the clinical trial operational or viable. Right? Um, you know, in some cases, we say, you know, you're not allowed to be on some particular set of medications. Well, you know, if you're working with people who have chronic medical illnesses, you're gonna have to allow concomitant medications. And sometimes you may not be happy about what you have to allow, but that's the reality of what you're the the universe you're operating in. Right? Particularly in psychiatry. Right? If you're gonna working in PTSD or you're gonna work in alcohol abuse, you know, there are compromises that you make, but those turn out to be in the service of this is more generalizable. Right? So that's the art part. How far do you go? You know, how far do you bend? You know, people take inclusion exclusion criteria, and there's this particular practice where you just copy and paste from the prior trial to the next one. Now I understand the efficiency of that one, but it's somewhat mindless in the sense that you need to really think carefully is, do I need all of these? Right? Um, which ones are absolute criteria? Which ones are nice to have? And even then, it's an art. ere you just copy and paste from the prior trial to the next one. Now I understand the efficiency of that one, but it's somewhat mindless in the sense that you need to really think carefully is, do I need all of these? Right? Um, which ones are absolute criteria? Which ones are nice to have? And even then, it's an art.

Brandon Li 26:18 Yeah. I'd love to talk about the the design of protocols and, uh, schedules of events and IE criteria a little bit here. I know that well, I I think I saw that you chaired GSK's, uh, protocol, um, review committee or something like that.

Michael Gold 26:33 For a while. Yeah. Yeah. Yeah. Also, DMS. Yeah. Right.

Brandon Li 26:36 Yeah. Um, what what what do you think that most people get wrong, um, when taking their first swing in a protocol?

Michael Gold 26:45 Um, most people get wrong. I think most people overload trials with too much data collection. Over the years, I become more and more fan of pragmatism in the trial. Right? So it's the KISS principle. Keep it simple, sca stupid. Um, sure. So I think people people ask they're they're asking too much and, you know, there's there's there's always this kind of sense of well, but it's but it's just another scale. It's another five minutes. No. Like, I get it, but it's more data that we're collecting. And so I keep on going back, and this is what we did at the at the protocol review committees, which is, what are you gonna use these data for? Right? And if it's a nice to have, get rid of it. If you must have it, right? Because then you're more vested in actually making sure you're collecting it, that it's of high quality. Right? You're gonna do it. You you you're prepared to stand behind the analysis of those kind of data. And I see, you know, a large number of studies where where it's just a lot of, you know, wouldn't it be interesting to think that, like, yeah. No.

Brandon Li 27:58 Yeah. Easy easy to miss the the forest for the trees, right, I guess.

Michael Gold 28:02 Well, I mean, it's it's you know, look. And and and I I mean it with all the love in my heart. I get where that comes from. Right? You're working a rare indication. It it's gonna be, you know, once in a lifetime study, and you wanna learn as much as you can. Right? So let's just pile it on. Or it's gonna be a difficult study to recruit for. Let's learn as much as we can. I I get that. I understand it. But, you know, it's it's you wanna focus on the nature of the experiment. What do you really wanna learn? Right? And every time that you keep on piling things on for participants in these studies, you know, they get frustrated, they're fatigued. Right? It's like, it's not really critical. Move on with it.

Brandon Li 28:46 Well, Mike, now you're calling my baby ugly. Uh, I just brought you a protocol, and you told me that it's all wrong. Um, what, uh, what techniques have you found in in having those, uh, those kinds of conversations as a leader? tigued. Right? It's like, it's not really critical. Move on with it. Well, Mike, now you're calling my baby ugly. Uh, I just brought you a protocol, and you told me that it's all wrong. Um, what, uh, what techniques have you found in in having those, uh, those kinds of conversations as a leader?

Michael Gold 28:56 I I mean so I so I think what what what what we learned was to actually force the dialogue between the various stakeholders and the teams that are driving the design. You know? What do you really want? What do you really need? What's critical? What what is, you know, can you answer some of these questions outside of a clinical trial? Right. So I'll I'll give you I'll give you an example because I think it's it's helpful. There are now online patient communities that you can talk to about certain aspects of the disease journey that don't require getting that information in the clinical trial. Right? Um, you can sit there and say, okay, you know, here's a list of five different outcome instruments that are all kinda designed to collect something similar. You know, there's a 50% or 70% overlap between these five instruments. Can you all get together, knock your heads together, go have dinner, come back and say of all the instruments out there, pick the one you wanna go with. Can you drive to consensus to sit there and say, Okay, is it good enough? Right? And again, what I what I learned chairing those committees, what I've learned reviewing dozens if not hundreds of protocols, is that there's often a lot of space to be, you know, you you can compress and you can find common ground to center and say, Look, what's good enough? It doesn't have to be perfect, but what's good enough? And is it good enough for the two of us? Can we then, you know, simplify a study? Right? That's that's right. Right. Sure. So you you

Brandon Li 30:30 mentioned, you know, status quo of maybe taking a prior protocol, copying it over, and using that as a as a starting point. And you suggest that maybe that's not the ideal practice. So what what what is? Can we then, you know, simplify a study? Right? That's that's right. Right. Sure. So you you mentioned, you know, status quo of maybe taking a prior protocol, copying it over, and using that as a as a starting point. And you suggest that maybe that's not the ideal practice. So what what what is?

Michael Gold 30:42 I mean, I think it's again, you you you can start with what was done in the past because I think there's value in all the work that was put in by predecessors to get to where they they took us. Then you look at and say, it doesn't make sense for what I wanna do now. Okay? Should I stick with exactly this the recipe that these people came up with ten or fifteen years ago? K? Again, as a teaching moment, right? So you look at PTSD studies where we're we're we're involved right now. Historically, many sponsors excluded any form of alcohol or substance abuse because they wanted to focus on the pure PTSD. Well, shit. A whole bunch of these people just couldn't enroll because that that patient population may not really exist. There's such high comorbidity. Right? So we've been looking at prior design and say, hey. Look. Let's operate with reality in front of us. Right? Like, let's deal with the real world as we know it now. And we decided to actually make some allowance for that comorbidity and allow it in our clinical trials. We didn't go full, uh, full full full force and say we're gonna allow everything in, but we made decision to allow somehow to moderate abuse in our clinical trial. We think that brings us one step closer to a more generalizable population or or more representative population. And hopefully, allows us to talk about the effect of of of COM three sixty in that patient population. But the the thought behind it was don't just mindlessly replicate what somebody's done before. And the reason I've seen that used over and over is, well, that's what regulators want. That's what regulators are used to. I don't, I don't, I don't buy that excuse whatsoever. Right? So I don't find those irrational. Do you have

Brandon Li 32:36 a more favorable view of, uh, of the regulators than, uh, before. And the reason I've seen that used over and over is, well, that's what regulators want. That's what regulators are used to. I don't, I don't, I don't buy that excuse whatsoever. Right? So I don't find those irrational. Do you have a more favorable view of, uh, of the regulators than, uh,

Michael Gold 32:40 Well, I think there's there's there's something to be said about certain elements of the design that are consistent. Right? There's a diagnostic criteria. You know, until you show me a better one, we're gonna stick with what people know. There's kind of an there there are known kind of psychometric parameters to that instrument. Right? Sensitivity, specificity, positive predictive value. Right? We we we know what we're gonna get and we know the limitations of the instrument. But there's an element of kinda sponsor side thinking and risk that, you know, I I think it's all too easy sometimes to just sit there and say, we abdicated in favor of what's been done 15 times before us. Not sure that's the way to go. Right? I mean, in particular, not if you're testing a new pharmacology where you may actually have an advantage where you can pick up signals in other areas. I mean, if I'm gonna do yet another triptan for my grade, I'm gonna go back to a design that's worked every time that has been done before. Right? In that case, there's no reason for me to innovate on the design. Right? I'm taking a novel pharmacology into a new patient population. I have every reason to give that compound every chance to show me what we what it can do in spaces that may be new.

Brandon Li 33:59 Yeah. Okay. So then let's let's layer on maybe the wrinkle of new technology. Um, so you're you've got you've got a new, like, a a new compound. You're leading the charge on this. Um, at what point do you think, um, yeah, maybe it is time to try, uh, a new wearable DCT, some of these, uh, newer techniques, uh, given it is it's new and new. et's let's layer on maybe the wrinkle of new technology. Um, so you're you've got you've got a new, like, a a new compound. You're leading the charge on this. Um, at what point do you think, um, yeah, maybe it is time to try, uh, a new wearable DCT, some of these, uh, newer techniques, uh, given it is it's new and new.

Michael Gold 34:22 Yeah. I mean, look, I'm a fan. Right? I'm a fan because, um, I think that technology has come a very long way to allow you to measure ecologically valid behaviors in a way that is reliable enough for use in clinical trials. Right? So you think about where things started, for example, in Parkinson's disease, you know, the ability to measure tremor or actigraphy. Right? That seemed like a you know, it was a low entry point, but a very valuable entry point to sit there and say, right, we can objectify something that is absurd. Uh, people objectified it or made it made it measurable. You could video somebody walking or doing an Archimedes certain things like that. Then we kinda digitize that and said, okay. Now instead of, you know, kind of doing an analog to digital version of the Archimedes, now a digital version of the tool. And now we have other ways we can just measure amplitude and frequency of the tremor in multiple dimensions. You can see that kinda generalizing in the sense of the tremor, the rigidity. Now it goes to gate, you know, gate analysis, so we have ways to figure out what's really going wrong in people with Parkinson's disease and their lack of balance, etcetera. So that was to me a great example of where technology really enabled smarter, faster, more efficient clinical trials. Right? And then you sit there and say it went into other domains, motor behavior, cognition, sleep, speech, um, you know, ways to actually infer mood without, you know, because if you sit to say, what what, you know, how are you feeling today? I'm not sure I need a device to do that. Right? But so I think I'm a fan of that. And and I think part of the reason that I'm, uh, I, and I go as a very early doctor, particularly at AbbVie, right, Is that it's this kind of repeated measures model. I can now collect data from your behavior continuously every day. As much data as you wanna give me, I will take because in some ways, that's kind of a regression to the mean. I now can really see trends over time. And one of the things that we learned sadly in in studies where we do a visit at baseline one at week six or week 12, if you have a really bad day at the end of the study, you know, you you're you're sick or something really bad happened, the entire benefit of the therapy could be mass massed by a really bad day. And so I think the value of those technologies is that it minimizes your, your vulnerability to within subject variation. Right. Now you, you probably thinking, well, when do you when do you use that technology going from a pivot, a pilot study to a pivotal trial? Right. I think we're starting to see more use of those in pivotal trials. When does it become the primary registrational output? That's a good question. Right? ubject variation. Right. Now you, you probably thinking, well, when do you when do you use that technology going from a pivot, a pilot study to a pivotal trial? Right. I think we're starting to see more use of those in pivotal trials. When does it become the primary registrational output? That's a good question. Right?

Brandon Li 37:19 Yeah. Yeah. Certainly, there has to be enough, uh, precedent data, I guess, uh, for for that tracking.

Michael Gold 37:25 Yeah. And I mean, I think the values that you can get beyond that we can measure symptom domains. Now we can measure things that are how a person is functioning. Right? If I can, um, hypothetically, I can see how you're driving your car, or I can see how you're operating at work, or I can I can get a better sense of, you know, your your your, uh, your interpersonal relations because I can see you get out of the house more, or the the inflection in your voice when you talk to friends, whatever it is, indicates an improvement in mood? I can start to make arguments that were beyond just measuring, you know, simple domains.

Brandon Li 38:02 Yeah. Now, Mike, uh, you started this conversation by saying, uh, let's slash as much of the data collection requests, uh, as we can. And now you're saying, well, actually, I love this data stream. Um, but which one is it?

Michael Gold 38:14 Well, it it's both. I mean, in in in the sense of that the thing that I like about, for example, wearables and sensors is that they're unintrusive. They don't require they don't require people to show up in clinic. You know, you do it at home. You do it in a way that is kind of doesn't interfere with quality of life. I mean, you know, I think I I think I shared this experience with you. We were working with a device called the MC 10 patch, which is a flexible patch that you put on your skin, and we were doing it in a study of multiple sclerosis looking at ambulation. And we had greater than a 100% compliance with the use of the compound, and we didn't have to push participants to put put the patch on. So when you have a technology that people in a study have no problem using and in fact, find it unobtrusive, right, And it, I don't think there's anything wrong with that. My, my objection is to need to have data that requires more clinic visits. It's more burden on the patient. You know, there's more missing data issues that that's why I start to question its utility.

Brandon Li 39:18 Yeah. Yeah. There's this, uh, there's this principle around fitting it into, uh, the natural pathways of of the individual's life.

Michael Gold 39:26 Right. Exactly. I mean yeah. You you know, it's like, is this drug helping you to live your life better? Right. That's the question. How is this helping you to live your life better? I'll figure a way to measure that. round fitting it into, uh, the natural pathways of of the individual's life. Right. Exactly. I mean yeah. You you know, it's like, is this drug helping you to live your life better? Right. That's the question. How is this helping you to live your life better? I'll figure a way to measure that.

Brandon Li 39:39 Yeah. Uh, a topic that comes up a lot when, uh, we speak to folks about operations and, uh, CloudOps excellence is working with sites. Yeah. I'd love to hear, uh, how you think about, uh, building, designing, cultivating, uh, site relationships, and, uh, ultimately motivating and and, like, maintaining great relationships even when things, uh, aren't going well. uh, we speak to folks about operations and, uh, CloudOps excellence is working with sites. Yeah. I'd love to hear, uh, how you think about, uh, building, designing, cultivating, uh, site relationships, and, uh, ultimately motivating and and, like, maintaining great relationships even when things, uh, aren't going well.

Michael Gold 40:02 No. It's so look. I I I I was an investigator for a bunch of years before I left academia to go to industry. So I have nothing but the utmost respect for people who are in that space, whether they're commercial research centers or academic research centers. It's a tough business. It's a really, really tough business. My sense is that working out and making sure that there is a very healthy relationship between every site and the sponsor is critical. And by healthy, I mean a relationship that can withstand difficult conversation difficult conversations. What's going on at your site? You know, you're not we're not seeing enough recruitment. We're seeing a lot of staff turnover. We're not seeing, you know, there's some glitches with the quality of the data. You know, we're worried about, you know, PI supervision. In my experience, my experience is that, you know, vast majority, vast majority of sites and investigators are ready for the right reasons. They're good people. They're really trying to do the right thing. Stuff happens. Right? And then I think our job is to what's going on? How can we help you? So, you know, part of part of what I encourage in my organization is very close dialogue with the sites. What I don't push for is trying to close a sale that says, you know, Doctor. So and so, will you commit to recruiting x number of people by next week? We're not in the business of closing sales. What we're in the business of is figuring out sites, how can we help them to get to where they wanna be in terms of the numbers that they've committed to us. Right? What do you need? Do you need help with recruitment? Do you need more money? Do you need some staff support? Where can I block and tackle for you? Right? Are you having issues with the CRO? Are there problems with the vendor? So one of the principles that I that I that I kinda live by is that, you know, I'm in this in the service of patients. I do this because I care about getting new drugs to patients to treat serious illnesses. From an operational perspective, we're in the service of sites. Right? There are in some ways, there are customer. If if they're not happy, if they're not if they don't have what they need, you're not gonna recruit the right patients. It's not about the volume of patients. I want them to recruit the right patients, high quality patients and collect high quality data, make sure that the patients are safeguarded. Right? I don't need any disasters, and I don't need to be in any headlines that says, you know, sponsor x, y, or z lost control of the study. Right? That to me comes from having a really healthy relationship with them, but it's also the notion that it's not a one off. We're not transactional. Right? You know, we wanna be with you on a journey because after this study, we'll come another study, and there may be the third one. Right? And so that's that's I think a lot of the value of of the long term relationship with the sites. Right? We get to know them. They get to know us. ne off. We're not transactional. Right? You know, we wanna be with you on a journey because after this study, we'll come another study, and there may be the third one. Right? And so that's that's I think a lot of the value of of the long term relationship with the sites. Right? We get to know them. They get to know us.

Brandon Li 43:08 I I I will say that the, um, we get to observe, uh, sponsor site relationships, uh, all the time in the in the course of, um, the work we do. And I will say that, um, uh, it is remarkable, uh, how much a, uh, a trust based relationship that is collaborative really, um, removes the needle in in terms of motivation and, uh, and overall study performance.

Michael Gold 43:37 No. I mean, look, I I've been in a situation where I've had a shutdown on a site, and and my conversation with Yves Saint, it it looked. It's not you as an individual, as a human being, parent, whatever it is. This study is not the right study for your site at this time. Let's let's park friends, and we'll come back to you when we have something, you know, and there are other occasions where it's, you know, we have to part ways because there's a problem here. Fix this stuff. Come talk to us. Let us know what you did, and we'll reengage. Right? I mean, sometimes doors close and open and things like that. Um, but, yeah, I I I think, you know, this is a it's an interesting conversation because sometimes CROs will will complain about, well, the site is meddling. They're, you know, there's there there's there's too many people are talking to the site, just confusion. And I think, yeah, there's some truth to that, and we have to work that one out. But, you know, having been both at the c at the at the sponsor level, at the CRO level, I'm not as a sponsor, I'm not willing to aggregate my primary relationship with the site. Right? I, you know, it's it's my compound, my study. Thank you. We'll work together. Right?

Brandon Li 44:43 I was I was gonna go there. Having, um, having done, uh, a ton of work on the sponsor side and sponsor service work on the CRO side, um, how how has the kind of combination of perspectives changed how you you kind of approach things today? mpound, my study. Thank you. We'll work together. Right? I was I was gonna go there. Having, um, having done, uh, a ton of work on the sponsor side and sponsor service work on the CRO side, um, how how has the kind of combination of perspectives changed how you you kind of approach things today?

Michael Gold 45:01 I mean, I look, you you may you may laugh at this, but I actually think we need to talk to people like adults, right, and treat someone like adults. Okay. Right? I mean, here's where it is. I'm happy to have the conversation with the CRO and say, guys, we love you, but we're going to maintain that close relationship with the sites. We're not gonna abandon that. We can figure out a way how we can coexist in that space so we're not talking across purposes. Right? I have that conversation with us here. I will have a similar conversation with my team, which is guys. Right? You gotta figure out a way not to be stepping all over the CRO to let them do their job. Now they got to talk to each other. How do we work it out? Right? Uh, and that's where I think, you know, adult con adults need to be in the room to have an adult conversation with how do we work it out? What are the rules of engagement? Where are the no go places? Right? Who do we need to talk to? Who are the point point point point accountability? Right? Yeah. If we hit a wall, how do we ask I mean, this is basic stuff. Right? But, fundamentally, it starts from forcing the the the grown up conversation and not sort of allowing people to devolve into their particular organizational silos.

Brandon Li 46:13 Yeah. Yeah. The it's, uh, it's almost a cliche, but it it really is one team. Um, and then, uh,

Michael Gold 46:22 I mean I mean, it was it was kind of interesting. We had a we had a local meetup here in Chicago, and there was a there was a a gentleman there who's starting a CRO, and and he he was asking couples to know, how how do you envision this working? You know, how would you make it work? And it's interesting because you know that when you, when you're working with a CRO, you'll get a team initially, and that team will change over time. And some people will be experienced. Some people are a junior. What he said to me is that somebody told him, I said, I'm happy to work with you. I will take the B and C players, I will whip them into shape, but I will keep them on my team. You don't get to move them around. Mhmm. Right? So it's that kinda one team mindset you were talking about. Right? Yeah. So this person is willing to work with, uh, average inexperienced CRO team, whip them into shape, but his his contractual ask is you don't get to play around and move people around in my team. As I bring him up to speed and I turn him to really, you know, first class drug developers, you don't get to you don't you don't get to abandon me. Yeah. Well, then if I'm if I'm

Brandon Li 47:30 If I'm gonna invest the time to train your team, uh, I would like for you to treat them as my team as well. Yeah. am. As I bring him up to speed and I turn him to really, you know, first class drug developers, you don't get to you don't you don't get to abandon me. Yeah. Well, then if I'm if I'm If I'm gonna invest the time to train your team, uh, I would like for you to treat them as my team as well. Yeah.

Michael Gold 47:34 Yeah. I mean, I had the experience running a study when I was was, you know, a CMO of a small company. We had a 100% turnover in our monitors every six months. My sites were were up in they're they're up in arms. Like, you know, we've gotta train yet another CRA because they can't keep these people. And as soon as they learn their stuff, as soon as they, you know, they go off to do other things. So I finally I, you know, I I I had one of those come to Jesus moments with the CRO. I said, you you cannot do this. I mean, contractually, I'm going to stop you from doing this because, essentially, you know, you're learning at my expense, and I'm not getting high quality data.

Brandon Li 48:09 Yeah. Well, that that's a hot tip for anybody listening, uh, uh, in terms of a negotiating ask, uh, if you're not already making it.

Michael Gold 48:17 Yeah. No. I mean, I I don't think there's anything wrong for sponsors to sit there and say, you know, look, I I accept the reality of the kind of team that I'm gonna get, but stability in whatever team you get, and I mean, really getting the CRO to commit to stabilizing a team is really, really important. That that that monitor or study coordinate, I mean, they're they're gonna have to work with the site too. They you know, their reputation's in it as well. So, you know Yeah. I can I you need to figure out how to make

Brandon Li 48:45 it a win win? Yeah. Of course. Mike, uh, in closing, I've got a few rapid fire questions for you,

Michael Gold 48:49 if you don't mind.

Brandon Li 48:50 Sure. Uh, how are you most excited to see, uh, the nature of, uh, operations and, uh, and studies change over the next ten years?

Michael Gold 48:57 Specifically, when in when in the psychedelic space or in general?

Brandon Li 49:00 Uh, let's go neuroscience. d: if you don't mind. Sure. Uh, how are you most excited to see, uh, the nature of, uh, operations and, uh, and studies change over the next ten years?

Michael Gold 48:57 Specifically, when in when in the psychedelic space or in general?

Brandon Li 49:00 Uh, let's go neuroscience.

Michael Gold 49:02 Okay. Um, I mean, I I I think part of it is at least in some areas, the the development revolution of biomarkers has been remarkable. Right? So if you think about Alzheimer's disease studies and availability of load based biomarkers, yeah, digital digital cognitive tools, these non invasive things. So I think the ability to implement studies in a more real world setting, I think is really, really impressive. Um, I think advancements in more advanced imaging, you know, certain pet ligands, you know, the use of MEG, fMRI, etcetera, etcetera, really is helping to kinda drive better design of early translational proof of mechanism studies. So I think I think that that that's helping. Um, I think on the back end, um, the ability to collect that a lot of the stuff digitally at home, right, minimizing number of clinic visits, minimizing sort of treatment effects or placebo effects that that that I think is making a lot of progress. Um, I think what I'm also seeing is a lot more regulatory curiosity and openness Sure. It's the new new types of instruments. Right? So that's helpful. What do you

Brandon Li 50:21 think is holding back change? izing sort of treatment effects or placebo effects that that that I think is making a lot of progress. Um, I think what I'm also seeing is a lot more regulatory curiosity and openness Sure. It's the new new types of instruments. Right? So that's helpful. What do you think is holding back change?

Michael Gold 50:25 I mean, I think right now in in The US, it's wholesale uncertainty about what that what that what that environment's gonna look like right there. We have no idea what, you know, the FDA is gonna look like or HHS is gonna look like. We don't know what the midterms are gonna bring. So just a lot of anxiety about where it's gonna go. Right? Uh, I think, you know, I I hear certain things that I like. You know, the national priority voucher, I think, was was a great idea, um, but, you know, how it's implemented is a different story. I think what's also holding folks back is is, you know, there were there was a period of, you know, serial successes in neuroscience, and then there are some pretty notable, you know, rocket crashes lately. Sure. Um, and so it the the pendulum kinda swings a little bit. Um, and I think that's also in neuroscience, there is this kind of pendular swing in terms of optimism. Right? Everybody was very happy when lecanimab and denanumab got approved. First, you know, disease modifiers, antiamyloid therapies. And then, you know, there was this kinda like, well, what's it really mean and how is it yielding, etcetera, etcetera. So real world application, real world benefit is becoming a little bit more difficult to demonstrate. So I think enthusiasm kind of peaks and, you know, goes. But but I think in general, what I what I'm sensing is, um, a recognition that we don't have a choice but to be engaged in neuroscience related clinical development. I mean, the on the medical need, the misery that is out there that remains unaddressed compels us morally to actually keep on going at it. I forget about the financial part of it, which if you do if you if you have a good drug and etcetera, it'll work, but I'm just morally robbing it.

Brandon Li 52:14 Yeah. Yeah. And certainly, uh, more and more, um, uh, the world is, uh, is fighting with these things, um, as we Yeah.

Michael Gold 52:24 Yeah. Yeah. I I mean, I completely agree. If you if you look at sort of, you know, mental health or neurodegeneration, this is not a it's not just a, you know, US, Western Europe problem anymore.

Brandon Li 52:34 It's not

Michael Gold 52:34 it hasn't been for a while. Yeah. Okay?

Brandon Li 52:37 Uh, so you've mentioned some things that you're excited about. Uh, what is overrated? ental health or neurodegeneration, this is not a it's not just a, you know, US, Western Europe problem anymore. It's not

Michael Gold 52:34 it hasn't been for a while. Yeah. Okay?

Brandon Li 52:37 Uh, so you've mentioned some things that you're excited about. Uh, what is overrated?

Michael Gold 52:43 What is overrated? Um, well, I'm gonna pose it as someone maybe rhetorical that what is overrated is people's fear of the FDA. Okay. K. And I think people people need to get over their, uh, you know, right. This is a group of really hardworking, dedicated folks that are committed to helping us advance, you know, public health in in this country and also in Europe and Japan, etcetera, etcetera. So I think what's overrated is fear of engaging with the regulators. I I I can't wait to have my conversation with these folks and get the best of their advice. Keep in mind that they probably have the broadest view of what's out there and what's being developed and new new new method, new trials, and, you know, so if if if there's an answer grape out there or some Oracle that can share wisdom, it's regulatory bodies, it's there. And so I think what's overrated is people's fear of them or unwillingness to engage or being overly cautious. Like, you know, just ask. God, just ask.

Brandon Li 53:56 Yeah. Absolutely. I love that. Um, they're not the, uh, not the boogeyman that's, um, that they make they made out to

Michael Gold 54:02 No. No. I mean and and I I think it's, you know, I think part of it is but be prepared. Right? You're a data guy. Show up with data. Yeah. Show up show up with a with with, you know, think it through. Right?

Brandon Li 54:13 Of course. Well, Mike, I have, uh, so enjoyed this conversation. Uh, any any last comments? Anything that I didn't ask that I should have?

Michael Gold 54:21 Uh, I mean, no. I mean, this has been thoroughly enjoyable. I mean, just just to kinda reiterate, you asked about the clinical science and the operational part of it. I just wanna make sure that if I were to close with a thought is it's all about doing it for the patients. Right? Making sure that we do the right studies. The design is important, but the execution is as important just to make sure that we're getting a clean answer. And at the end of the day, the study may not work or the drug fails. That's all well and good, but everybody can walk away with a clean conscience knowing that you've answered that question, you're done, move on. Right? That that's that's sort of the most important thing for me.

Brandon Li 54:58 Yeah. Yeah. I I love the way you kind of framed at the beginning, which is, uh, just a paraphrase of we we have almost a moral obligation in research to to do good research, um, on behalf of the the people who decide to participate.

Michael Gold 55:10 Right. I mean, imagine that you're putting a a a family member, a a child or a spouse or a significant other, and you said, oh, you wanna be in a clinical trial. What would you want? Right? Well, I wanted to make sure it's run really, really well. I don't want the contribution to be wasted. e. Right. I mean, imagine that you're putting a a a family member, a a child or a spouse or a significant other, and you said, oh, you wanna be in a clinical trial. What would you want? Right? Well, I wanted to make sure it's run really, really well. I don't want the contribution to be wasted.

Brandon Li 55:27 Absolutely. Absolutely. Powerful stuff, Mike. Alright. My pleasure. Thanks again for joining me here.